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Cancer patients demand a high level of involvement in decisions concerning treatment. Many patients are informed about
experimental trials, and especially the first consultation may be crucial for the future communication and treatment process. Patients
with nonresectable non-small-cell lung cancer or colorectal cancer informed about experimental chemotherapy completed a
questionnaire on satisfaction with the communication process, general attitude towards experimental treatments, the substance of
information, and personal contact with the physician following their first consultation in a medical oncology unit. Physicians completed
a questionnaire on their perception of the patients’ satisfaction. Among 68 physician–cancer patient pairs, 29 patients were informed
on chemotherapy in randomised trials and 39 in nonrandomised studies. The general attitude towards experimental treatment was
positive or very positive in 71% of patients. Information on the treatment was perceived as completely adequate in 93% of patients
informed on randomised and in 67% informed on nonrandomised trials. Physicians underestimated the patients’ satisfaction with the
overall communication process, the personal contact, the patients’ perceived sufficiency of the specific treatment information and
their ability to decide on study entry. In conclusion, considerable differences were observed between patients informed about
experimental chemotherapy in randomised and nonrandomised trials, both with respect to their perception of how adequate the
information on the specific treatments were, and whether it was sufficient for decisions on study entry. This study type effect should
be accounted for in future evaluations of communication and patient satisfaction. The data also support the fact that cancer patients
have a desire for and ability to understand rather detailed and comprehensive treatment information.
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Contemporary cancer patients expect a higher level of involvement
in the consultation than they have previously, and this preference
is now recognised by most physicians (Oken, 1961; Novack et al,
1979) This preference for involvement is accompanied by
increasing expectations to be fully informed on issues relating to
diagnosis, prognosis, treatment options, and their likelihood of
success. The physician must also be mindful that the diagnosis of a
malignant disease is one of the most significant events in the life of
any individual (Siminoff, 1992; Spiro, 1992; Sardell and Trierwei-
ler, 1993). Especially, the first consultation is crucial for the
patients’ perception of the entire situation and for the future
communication and treatment process. Further complications in
the communication process may occur when the treatment offered
is experimental within a clinical trial. In this case, the patients’
satisfaction with the information process is essential for their
understanding of their illness and the complex combinations of
treatment and drugs that are used, and also for compliance with
instructions and treatment plans (Ley et al, 1976; Ley, 1982; Kaplan
et al, 1996).
Patients are more likely to be satisfied with the physician–
patient interaction when physicians provide clear information, are
sensitive to the patients’ needs, answer patient questions
and do not dominate the exchange (Stiles et al, 1979; Smith et al,
1981; Blanchard et al, 1990; Bertakis et al, 1991). Discrepancies
between the patients’ and the physicians’ expectations of the
consultation may possibly influence the outcome and the level of
satisfaction.
The aim of this study was to evaluate the physician–patient
communication process during the cancer patients’ first visit to the
medical oncology unit to be informed about the possibility for
entry into a clinical study (phase II or Phase III trial) with
chemotherapy. The issues under evaluation were: (a) the patients’
satisfaction with the communication process as a whole, (b) the
physicians’ perception of the patients’ satisfaction with the
communication, (c) the influence of the patients’ general attitude
towards experimental treatment, and (d) the influence of the
physicians’ charge and experience in medical oncology.
MATERIAL AND METHODS
Eligible patients had nonresectable non-small-cell lung cancer or
colorectal cancer and were referred to the medical oncology unit
for chemotherapy. Only patients who were informed about
treatment within a clinical trial, being either phase II or phase
III studies, were included. The clinical studies informed about were
accepted by the health authorities and by the ethical committee,
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lwhile the communication study was accepted by the ethical
committee.
The patients were informed about the communication study
immediately before their first consultation in the ward. This
information was given by a physician other than the physician who
should have the consultation with the patient. The information was
both verbal and in writing and written informed consent was
obtained. The physician to have the consultation also gave written
informed consent to participate following verbal and written
information.
The attending physician was obliged to perform the following
duties during the first consultation: (a) make the patient aware of
the malignant diagnosis (all patients were referred from other
departments that had diagnosed the malignant disease and that
had informed the patient about it), (b) inform about the prognosis
with and without therapeutic intervention, (c) inform about the
nature, risk, and benefits of the proposed intervention, including
mentioning the patients’ right to self-determination and hand-out
of written information, (d) inform about normal standard
treatment outside of the clinical study, and (e) mention the
likelihood of success both with the experimental treatment as well
as the alternative standard treatment. Informed consent for the
clinical treatment study was not to be obtained during the patients’
first consultation, as this served solely informative purposes and
all patients were informed neither to give nor refuse consent before
the following visit.
The attending physician who was to inform the patient during
this first consultation could according to the traditional organisa-
tion of the hospital wards in Denmark be either a consultant, a
resident, or an intern as well. Residents are physicians who have
completed a clinical education programme of minimum 5 years
together with 8–10 formalised postgraduate courses. Interns are
physicians who are in the process of completing this programme
and they are in departments of oncology usually already quite
skilled, though not yet fulfilling the criteria for being a resident.
Very specified and written instructions regarding information of
patients are necessary and in routine use, both to cover for the
differences in education and for reasons of legislation. Thus, the
clinic’s usual routine for obtaining consent, a procedure that was
similar for standard treatments and for experimental treatments
within a clinical trial, was followed: the attending physician
provided the patients with both verbal and written information
during the patients’ first visit to the clinic, and both the patients
and their relatives had the opportunity to ask questions. Also, the
legislation concerning clinical trials and patients’ autonomy in
treatment decisions was described and a written summary of this
legislation was given. On the subsequent visit, the patient had a
new consultation with the attending physician, during which the
patient and the relatives could again ask further questions. The
patient was asked to sign the particular written patient information
sheet if any treatment were to be embarked on, independent of that
being either a standard treatment or an experimental treatment
within a clinical trial; one copy of this was kept by the patient and
one was kept with the patient record.
With respect to the minimum requirements of knowledge to be
conferred to the patients and their relatives concerning the disease,
possible complications, treatment possibilities, and prognosis, this
was outlined for physicians attending the ward in an eight-page
manual concerning colorectal cancer and in an 11-page manual
concerning non-small-cell lung cancer, respectively. With respect
to possible benefits, side effects, and complications to standard
treatments, this was outlined for the physicians in the manual
described above and for the patients in the written patient
information in addition to the verbal explanation. Similar
information concerning experimental treatments in clinical studies
was described for the physicians in the experimental protocols and
for the patients in the written patient information concerning the
study in addition to the verbal explanation. These disease-oriented
manuals, protocols on experimental treatments, and written
patient information sheets for both standard and experimental
treatments facilitated uniform information to patients as far as
possible. There was, however, no audit of the information given
and some variations in these might still exist. Each consultation
during the first visit to the clinic was scheduled for 1h and the
subsequent visit was scheduled for half an hour.
Both the patient and the physician completed a questionnaire of
six items and four items, respectively, immediately following the
consultation. Each patient–physician pair was unaware of each
others’ answers to the questionnaire, as these were collected by
another physician. There were no questionnaires for relatives
participating in the consultation.
The following patient characteristics were registered: age,
gender, diagnosis, accompanied by relatives during consultation,
and type of clinical treatment study (randomised or nonrando-
mised). The patient questionnaire asked about the following six
items: satisfaction with the communication process overall, with
the personal contact with the physician, with the specific
information concerning the experimental treatment, whether the
information was sufficient to decide on consent or not to
experimental treatment, whether there was sufficient possibility
to ask questions, and about the patients’ general attitude to
experimental treatment studies not taking the actual one into
account. No formal information was sought from the relatives, but
the relatives could assist the patient in answering the ques-
tionnaire.
The following physician characteristics were recorded: age,
gender, charge, duration of experience as physician, and duration
of experience in oncology. The physician questionnaire asked
about the following four items: the physicians’ perception of the
patients’ satisfaction with the communication process overall,
the personal contact with the patient, perception of the
patients’ satisfaction with the specific information concerning
the experimental treatment, and perception on whether the
patient may be able to decide on consent or not to experimental
treatment. Answers were given according to five-point Likert
scales.
RESULTS
A total of 68 patient–physician pairs were evaluated. These 68
patients’ characteristics are shown in Table 1. Most patients were
men (69%), the median age was 59 years, and the majority had
lung cancer (54%). About half of the patients (48%) were informed
about treatment within a randomised study, and most patients had
followed the advice to be accompanied by a relative (77%). The
characteristics of the 25 physicians who participated in the study
are shown in Table 1. The median age was 36 years and 56% were
males. Three consultants (12%) participated in the study, while the
majority of physicians were interns, that is physicians undergoing
postgraduate clinical training (56%). The median experience as a
physician was 10 years and the median oncologic experience 4
years overall. For interns, these figures were 6 years (range 1–13
years) and 1 year (range 1–4 years), while it was 15 years (range
6–18 years) and 10 years (range 6–14 years) for residents,
respectively. All the first consultations evaluated lasted 1h each.
The patients’ satisfaction with the entire communication during
the consultation is shown in Table 2, together with the perception
by the physicians of how they believed the patients rated the
communication. While the patients in 66% of cases rated the
communication as ‘very good’ this was only the case for 26% of the
physicians’ evaluations. Only 3% of patients’ evaluations rated
‘acceptable’ and none rated ‘poor’. Similar figures for physicians
were in contrast 28 and 2%, respectively. When splitting the
physicians’ evaluations into a more experienced group (consul-
tants and residents, 49 patient–physician pairs) and a less
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differences were observed (Table 2).
The personal contact was perceived as ‘very good’ or ‘good’ by
69 and 31% of patients, but was perceived less good by physicians
(32 and 50%, respectively). It was even rated as ‘poor’ by the
physicians in 4% of cases (Table 3). Regarding the satisfaction with
the information concerning the experimental chemotherapy within
either phase II or phase III trials, most patients (78%) found it
‘completely adequate’. Only 3% found it ‘less acceptable’ and none
found it ‘insufficient’ or ‘too detailed’. The corresponding figures
for the physicians’ perception of the patients’ evaluation on this
subject are shown in Table 4. It is of interest that the physicians in
15% of cases believed that the patients found that it was ‘too
detailed’. Table 4 shows the patients’ satisfaction according to
whether it was information concerning a randomised phase III
study or a nonrandomised phase II treatment. A somewhat higher
proportion found the information concerning the randomised
study ‘completely adequate’ than was the case for nonrandomised
studies, the figures being 93 and 67%, respectively.
The sufficiency of the information with respect to enabling the
patients to later decide whether or not to consent on the
experimental treatment was evaluated by both patients and
physicians (Table 5). The evaluation that the information given
made the patient ‘able to decide’ was given by 91% of patients,
which contrasted somewhat to the physicians’ answers, who in
21% of cases perceived that the patients were ‘unable to decide’.
This perceived sufficiency of information was further analysed
according to study type (randomised or nonrandomised), and
according to physicians’ charge (Table 5). All patients informed
about a randomised study felt ‘able to decide’, while the same
holds true for 85% of cases with nonrandomised studies.
Physicians’ perception on the matter was independent of their
charge (Table 5). Even though the majority of patients (52 patients
(75%)) indicated that the information given concerning their
malignant disease was sufficient, 13 patients (19%) felt that they
had not received sufficient information on their illness when the
physician started information on treatment options including
experimental chemotherapy. Four patients did not respond to this
particular question.
The patients’ general attitude towards experimental treatments,
that is not the particular study under consideration but their basic
feeling about such treatment propositions, is shown in Table 6. It is
also analysed according to the proposed study type (randomised
or nonrandomised) under consideration. Only one patient (2%)
was ‘very negative’ about the thought of an experimental
treatment, while 66 out of 68 patients (96%) were either ‘neutral’,
‘positive’, or ‘very positive’. No differences were noted among
patients informed about randomised or nonrandomised experi-
mental treatments.
Table 1 Characteristics of 68 physician–cancer patient pairs
Patients, n¼68 Physicians, n¼25
n(%)
Gender
Male 47 (69%) 14 (56%)
Female 21 (30%) 11 (44%)
Age (years)
Median 59 36
Range 37–79 26–48
Diagnosis
Lung cancer 37 (54%)
Colorectal cancer 31 (45%)
Relatives present
No 16 (23%)
Yes 53 (77%)
Randomised study
No 36 (52%)
Yes 33 (48%)
Physicians charge
Consultant 3 (12%)
Resident 8 (32%)
Intern 14 (56%)
Experience as physician (years)
Median 10
Range 1–18
Experience in oncology (years)
Median 4
Range 1–14
Table 2 Patients’ satisfaction with the entire communication process
during thefirst consultation and physicians’ perception of their patients’
satisfaction
Physicians
Evaluation
Patients,
n¼68
Cons.+Res.
(49 pt./phys.pairs)
Interns
(19 pt./phys.pairs)
Very good 45 (66%) 13 (27%) 5 (26%)
Good 21 (31%) 21 (43%) 9 (47%)
Acceptable 2 (3%) 14 (29%) 5 (26%)
Poor 0 1 (2%) 0
Not acceptable 0 0 0
Unanswered 0
Abbreviations: Cons.¼consultants; Res.¼residents; pt./phys. pairs¼patient/physi-
cians pairs.
Table 3 Evaluation of the personal contact during first consultation by
68 physician–cancer patient pairs
Patients Physicians
Personal contact n (%) n (%)
Very good 47 (69%) 22 (32%)
Good 21 (31%) 34 (50%)
Acceptable 0 9 (13%)
Poor 0 3 (4%)
Unacceptable 0 0
Unanswered 0 0
Table 4 Satisfaction of the information on experimental chemotherapy
during the first consultation by 68 cancer patients and their physicians’
perception of the patients’ level of satisfaction
Patients
Satisfaction
Randomised
study (n¼29)
Nonrandomised
study (n¼39) Physicians
Completely adequate 27 (93%) 26 (67%) 42 (62%)
Acceptable 1 (3%) 8 (21%) 15 (22%)
Less acceptable 0 1 (3%) 1 (2%)
Insufficient 0 0 0
Too detailed 0 0 10 (15%)
Unanswered 1 (3%) 4 (10%) 0
Physician–cancer patient communication
JB Srensen et al
330
British Journal of Cancer (2004) 90(2), 328–332 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lDISCUSSION
Effective patient–physician communication is critical to the
informed consent process necessary for appropriate cancer
therapy (Siminoff, 1992; Butow et al, 1995; Ong et al, 1995;
Bennett and Alison, 1996), and surveys have shown that patients
want a high degree of information and the information usually
produces a positive effect (Fallowfield et al, 1995; Meredith et al,
1996). Others have pointed out that the information needs to be
individualised (Butow et al, 1997), and also the expectations of the
patients have been evaluated in relation to satisfaction with the
consultation (Brown et al, 1997). A specific, but far from rare,
situation is when the responsibility of the physician is the
discussion of investigational therapies. Although several standard
regimens may have been described in the literature, there is
typically a consensus among oncologists that the current state of
management is unsatisfactory, and that one reasonable option is to
suggest the patient to be enrolled in a prospective clinical trial. In
such cases, another dimension in the communication process is
added to the already complex situation. This situation was the
focus of the current study, which revealed that the attitude of the
patients is generally in favour of participation in a clinical trial,
with 71% being either positive or very positive, and only 2% being
negative (Table 6). This general statement may, however, not
necessarily reflect in the patients’ attitude towards a particular
experimental treatment being suggested, as this is an area in which
the entire actual communication process may influence in addition
the patients’ basic attitude towards the subject. The perception of
this total communication process was stated as either ‘good’ or
‘very good’ by 97% of patients (Table 2), a figure that might be
influenced by factors such as the previously mentioned attitude
to experimental treatments in general, or by the actual commu-
nication process including the specific information given. Also, the
patients’ perception of the personal contact to the physician, which
was rated as ‘good’ or ‘very good’ by patients (Table 3), may have
contributed to the patients’ impression of the communication
process and hence the perception of sufficiency of the information
given.
A primary responsibility of the physician is to impart factual,
reasonable, and appropriate information so that the patient is
appropriately informed and enabled to make reasonable decisions
relative to treatment options. Moreover, the data show marked
clinical improvement in patients with advanced cancer who are
able truly to collaborate with their physicians on account of their
thorough understanding of the treatment (Shapiro, 1998). The
information on the experimental treatments was perceived as
‘completely adequate’ in 78% of patients, but were accordingly less
satisfactory in 22% of cases (Table 4). Especially the latter patient
group may be very interesting in order to offer more satisfactory
information to future patients. One possible explanation for the
latter group is the observation of more patients having the
perception of completely adequate information when informed
about randomised trials in contrast to those informed on
nonrandomised experimental treatment (Table 4). Even though
both the verbal and written information on the first subject was
more comprehensive than for the apparently more straightforward
concept of nonrandomised treatment, this comprehensiveness may
be requested by the patients. This concept of comprehensive
information is in accordance with a study on 250 patients at an
oncology centre in Scotland, which showed that 79% of patients
wanted as much information as possible (Meredith et al, 1996).
The proportion of patients who wanted to know the chance of cure
and the side effects of therapy was 91 and 94%, respectively. It is
accordingly of interest for future treatment studies that also the
current study focusing solely on patients receiving experimental
chemotherapy pointed towards more extensive information on the
treatment in itself being perceived as beneficial and not burden-
some as may otherwise be feared.
An interesting observation in this study was that the physicians
underestimated both the patients’ perception of the entire
communication process (Table 2), the perceived adequacy of
treatment information (Table 4), the patients’ ability to decide on
whether or not to participate in the experimental treatment
(Table 5), and also perceived a less good contact with the patient
than vice versa (Table 3). There were no differences between
physicians’ perception according to charge (Tables 2 and 5). The
reasons for these observations are unclear. One explanation may
be that the physicians took a very cautious viewpoint in order not
to overestimate their own contribution. Another may be that the
patients’ ability to comprehend and the desire to obtain
information was truly underestimated. The latter explanation is
in accordance with the finding by others suggesting that physicians
have difficulties in estimating the amount and type of information
that patients want and their effectiveness in imparting information
(Blanchard et al, 1988; Mackillop et al, 1988; Wiggers et al, 1990).
Many difficulties are attributed to the evaluation of the
communication process. Previous studies have revealed predictors
of information and involvement preferences, such as age, gender,
and education (Cassileth et al, 1990; Hack et al, 1994), or
situational factors such as purpose and type of consultation (e.g.
new patient or later follow-up) and the presence or absence of a
companion (Beisecker, 1990; Beisecker and Moore, 1994). In
addition, a number of other, hitherto unknown factors may be of
influence. This raises a number of methodological deficiencies in
the current study, which should be addressed in future research.
Table 5 Evaluation of the information on experimental chemotherapy during the first consultation by 68 physician–cancer patient pairs: patients’ self-
estimation of ability to consent or not and physicians’ perception of the patients’ ability
Patients Physicians
Evaluation Randomised study (29 patients) Nonrandomised (39 patients) Cons.+Res. (49 p/p pairs) Interns (19 p/p pairs)
Able to decide 29 (100%) 33 (85%) 39 (80%) 15 (79%)
Unable/uncertain 0 2 (5%) 11 (20%) 3 (16%)
Unanswered 0 4 (10%) 0 1 (5%)
Abbreviations: Cons.¼consultants; Res.¼residents; p/p pairs¼physician–cancer patient pairs.
Table 6 Cancer patients’ general attitude towards experimental
treatments, divided into 29 patients informed about chemotherapy within
a randomised trial and 39 informed about a nonrandomised trial
General attitude
Randomised study
(29 patients)
Nonrandomised study
(39 patients)
Very positive 7 (24%) 5 (13%)
Positive 15 (52%) 21 (54%)
Neutral 6 (21%) 12 (31%)
Negative 0 0
Very negative 1 (3%) 0
Unanswered 0 1 (3%)
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experimental treatment and to other questions related to their
expectations for the communication should be given before the
consultation, followed by a questionnaire on the perception of the
consultation itself. As previously pointed out, these two inherently
different types of questions might otherwise influence each other
and blur the information obtained. Secondly, the situational
factors and the patient-related factors should be either homo-
geneous or at least registered and accounted for. With respect to
situational factors, these were somewhat standardised as all
consultations were with new patients having their first visit to
the department and all were informed on prefixed subjects,
including information concerning experimental chemotherapy to
all patients. However, as documented by the current results,
differences in the type of investigational treatment (i.e. rando-
mised or nonrandomised trials) under question may influence the
patients’ perception of the communication process and should
hence either be accounted for or standardised to only one type of
experimental treatment under investigation. With respect to
patient-related factors, educational status was not recorded, which
could be an important predictor of information and involvement
preferences, and must as such be accounted for in future studies.
Another difficulty in the evaluation of the communication
process is the lack of objective audit concerning both content and
form. Thus, the subjective reports of the communication may not
necessarily bear much relationship to what objectively happened.
This study does not provide an answer to that particular problem,
which must be dealt with in subsequent investigations in this field.
In conclusion, the majority of patients (71%) reported a positive
or very positive attitude towards experimental chemotherapy, 97%
perceived the general communication process during their first
visit to the clinic as either good or very good, and all rated the
personal contact with the physician as good or very good.
Considerable differences were observed between patients informed
about randomised and nonrandomised experimental chemother-
apy with respect to their perception of how adequate the
information on the specific treatment was and whether it was
sufficient for decisions on study consent. This should, in future
studies, either be accounted for or all patients should be under
evaluation for similar treatments. Physicians seem to under-
estimate the patients’ ability to comprehend and desire to obtain
information. These data support reports in the literature pointing
towards patients’ desire for and ability to understand rather
detailed and comprehensive information.
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